Our findings demonstrate that IL-22 produced by ILC3s is essential to inhibit excess inflammation and epithelial cell damage in T2DM mice infected with Mtb. Further understanding of these mechanisms and human studies can help to treat TB patients with T2DM. Here, IL22 is linked to type 2 diabetes mellitus.